Literature DB >> 26004651

Intestinal microsporidiosis.

Andrew S Field1, Danny A Milner2.   

Abstract

Infection by the ingested pathogens of microsporidia occur primarily in immunosuppressed patients (including untreated HIV/AIDS) and are diagnosed by stool examination, small bowel biopsy with special stains, or electron microscopy (for definitive speciation), or by various molecular techniques. Although electron microscopy has been the definitive diagnostic tool for speciation, genetic sequencing increasingly provides the definitive diagnosis for new species, such as Anncaliia algerae. Further genetic sequencing of the common pathogens may allow for the development of advanced molecular diagnostics providing high diagnostic sensitivity and throughput.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AIDS; Diarrhea; Enteritis; HIV; Immunosuppression; Microsporidium; Warthin-Starry

Mesh:

Year:  2015        PMID: 26004651     DOI: 10.1016/j.cll.2015.02.011

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN: 0272-2712            Impact factor:   1.935


  9 in total

Review 1.  Therapeutic targets for the treatment of microsporidiosis in humans.

Authors:  Bing Han; Louis M Weiss
Journal:  Expert Opin Ther Targets       Date:  2018-11-01       Impact factor: 6.902

2.  The first study on opportunistic intestinal microsporidiosis in IBD patients receiving immunosuppressive medications in Iran.

Authors:  Z Hasani; H Asadzadeh Aghdaei; H Balaii; M Azimirad; E S Mirsamadi; H Mirjalali; M R Zali
Journal:  Epidemiol Infect       Date:  2017-05-15       Impact factor: 4.434

3.  Enterocytozoon bieneusi detected by molecular methods in raw sewage and treated effluent from a combined system in Brazil.

Authors:  Sandra Yamashiro; Vagner Ricardo da Silva Fiuza; Ângela Therezinha Lauand Sampaio Teixeira; Nilson Branco; Carlos Emílio Levy; Isabel Cristina Vidal Siqueira de Castro; Regina Maura Bueno Franco
Journal:  Mem Inst Oswaldo Cruz       Date:  2017-06       Impact factor: 2.743

4.  First characterization of a microsporidial triosephosphate isomerase and the biochemical mechanisms of its inactivation to propose a new druggable target.

Authors:  Itzhel García-Torres; Ignacio De la Mora-De la Mora; Gloria Hernández-Alcántara; Dora Molina-Ortiz; Silvia Caballero-Salazar; Alfonso Olivos-García; Gabriela Nava; Gabriel López-Velázquez; Sergio Enríquez-Flores
Journal:  Sci Rep       Date:  2018-06-05       Impact factor: 4.379

5.  Cyclophosphamide Treatment Mimics Sub-Lethal Infections With Encephalitozoon intestinalis in Immunocompromised Individuals.

Authors:  Maria Lucia Costa de Moura; Anuska Marcelino Alvares-Saraiva; Elizabeth Cristina Pérez; José Guilherme Xavier; Diva Denelle Spadacci-Morena; Carla Renata Serantoni Moysés; Paulo Ricardo Dell'Armelina Rocha; Maria Anete Lallo
Journal:  Front Microbiol       Date:  2019-09-25       Impact factor: 5.640

Review 6.  Microsporidia, a Highly Adaptive Organism and Its Host Expansion to Humans.

Authors:  Nirin Seatamanoch; Switt Kongdachalert; Sakone Sunantaraporn; Padet Siriyasatien; Narisa Brownell
Journal:  Front Cell Infect Microbiol       Date:  2022-06-16       Impact factor: 6.073

7.  Comparative Assessment of In-House Real-Time PCRs Targeting Enteric Disease-Associated Microsporidia in Human Stool Samples.

Authors:  Konstantin Tanida; Andreas Hahn; Kirsten Alexandra Eberhardt; Egbert Tannich; Olfert Landt; Simone Kann; Torsten Feldt; Fred Stephen Sarfo; Veronica Di Cristanziano; Hagen Frickmann; Ulrike Loderstädt
Journal:  Pathogens       Date:  2021-05-26

Review 8.  Microsporidial myositis in adult-onset immunodeficiency: case-based review.

Authors:  T G Sundaram; Amita Aggarwal; Sujata Ganguly; Elgiva Khristie Iangngap; Rungmei S K Marak; Latika Gupta
Journal:  Rheumatol Int       Date:  2019-09-09       Impact factor: 3.580

9.  Cutaneous microsporidiosis in an immunosuppressed patient.

Authors:  Daniel A Nadelman; Ashley R Bradt; Yvonne Qvarnstrom; Cynthia S Goldsmith; Sherif R Zaki; Frank Wang; Emily H Smith; Douglas R Fullen
Journal:  J Cutan Pathol       Date:  2020-03-20       Impact factor: 1.458

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.